Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Five Prime Therapeutics, Inc. Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-03-2013 11:30 AM
Nov 20 13
Five Prime Therapeutics, Inc. Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-03-2013 11:30 AM. Venue: The New York Palace Hotel, 455 Madison Avenue, New York, NY 10022, United States. Speakers: Lewis T. Williams, Founder, Chief Executive Officer, President and Director.
Five Prime Therapeutics, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013; Provides Cash Flow Guidance for the Full Year of 2014
Nov 12 13
Five Prime Therapeutics, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported collaboration revenues of $3,482,000 compared with $2,862,000 for the same period a year ago. Loss from operations was $7,318,000 compared with $5,905,000 for the same period a year ago. Net loss was $7,234,000 or $2.74 per basic and diluted share compared with $5,858,000 or $4.85 per basic and diluted share for the same period a year ago.
For the nine months, the company reported collaboration revenues of $10,006,000 compared with $7,059,000 for the same period a year ago. Loss from operations was $22,087,000 compared with $20,937,000 for the same period a year ago. Net loss was $21,555,000 or $12.60 per basic and diluted share compared with $20,782,000 or $17.46 per basic and diluted share for the same period a year ago.
The company provided cash flow guidance for the full year of 2013. The company expects full-year 2013 net cash used in operating activities of $28 to $30 million and to end 2013 with $73 to $75 million in cash, cash equivalents and marketable securities.
Five Prime Announces Licensing Deal with ADC Therapeutics
Nov 5 13
ADC Therapeutics Sarl will use antibodies licensed from Five Prime Therapeutics Inc. to develop cancer drugs in one of the biotech industry's hottest areas, antibody-drug conjugates. Five Prime did not disclose financial terms of its deal with ADC Therapeutics Sarl. ADC Therapeutics will start preclinical research and development of antibody-drug conjugates using antibodies licensed from Five Prime. ADCs are a hot area of drug development.